
- >
- Online Doctor >
- Insomnia >
- Daridorexant (Quviviq)




Quviviq contains the active ingredient daridorexant and is used to treat chronic insomnia in adults.
It is suitable for adults whose insomnia symptoms have lasted for at least 3 months and are having a meaningful impact on daytime functioning. It is used in adults with symptoms on 3 or more nights per week.
Yes. Quviviq may help improve daytime functioning as well as nighttime sleep outcomes.
It is recommended for adults with chronic insomnia only if CBT-I has been tried but not worked, or is unavailable or unsuitable.
The recommended adult dose in the attached material is one tablet once a night, every night, taken within 30 minutes before going to bed.
Yes.
If you forget to take Quviviq at bedtime, do not take that dose later during the night.
Yes. It can be taken with or without food, but it may take longer to work if taken with, or soon after, a large meal.
No. Patients should be advised to avoid drinking alcohol with Quviviq.
You should avoid driving or operating heavy machinery unless you feel fully alert, especially in the first few days of treatment.
Yes. You should avoid consuming grapefruit or grapefruit juice while taking Quviviq (daridorexant) because it can significantly increase the concentration of the drug in your blood, leading to a higher risk of serious side effects.
Patients with moderate hepatic impairment may need 25 mg, and it is not recommended in severe hepatic impairment.
There are no data in pregnant women, and it should only be used if the clinical condition requires treatment.
Yes. Patients are advised to continue to practise good sleep habits while taking Quviviq.
Quviviq (daridorexant) showed no evidence of physical dependence/withdrawal in insomnia trials, while noting recognised abuse potential and appropriate caution.